# GSK2251052 in Complicated Urinary Tract Infection

> **NCT01381549** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Infections, Urinary Tract

## Interventions

- **DRUG:** GSK2251052
- **DRUG:** imipenem-cilastatin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01381549
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-28
- **Primary completion:** 2012-03-06
- **Final completion:** 2012-03-06
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Microbiological findings of resistance on therapy in patients with complicated urinary tract infection
- **Last updated:** 2017-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381549, "GSK2251052 in Complicated Urinary Tract Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01381549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*